Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ: AMGN), Biogen (NASDAQ: BIIB), Gilead (NASDAQ ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Maxim Group analyst Jason McCarthy maintained a Buy rating on Oncolytics Biotech (ONCY – Research Report) yesterday and set a price ...

Ultimately, experts believe AI in drug discovery will lead to better drugs being developed faster. Here are four AI-oriented ...

Sagimet Biosciences eyes major opportunities in MASH and Acne treatments. Find out why SGMT stock is a solid pick with upcoming phase 3 study results.

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

We take a look at 4 Pharma & Biotech companies whose share prices rallied in October on the back of positive announcements.

Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the ...